Madison Avenue Partners has recently made a significant investment, acquiring a substantial stake in Indivior, a specialty pharmaceutical firm. This move comes as Indivior's stock has demonstrated impressive growth, nearly tripling in value over the past year. The investment underscores the fund's confidence in Indivior's market position, especially its leading product, SUBLOCADE, which is a key treatment for opioid use disorder. This strategic allocation reflects a positive outlook on the company's future performance and its ability to continue expanding within the pharmaceutical sector.
On May 15, 2026, Madison Avenue Partners formally announced its new holding in Indivior through an SEC filing. During the first quarter, the firm acquired 4,315,162 shares, representing an estimated transaction value of $142.51 million, calculated based on the average closing prices during that period. By the end of the quarter, the total value of this new position was approximately $131.53 million, factoring in both trading activities and market price fluctuations. This substantial purchase constituted 5.72% of Madison Avenue Partners' reportable U.S. equity assets under management as of March 31, 2026.
Indivior specializes in the development and commercialization of buprenorphine-based prescription medications, including well-known products like Suboxone Film and Subutex Tablet. These treatments primarily target opioid dependence. The company operates a specialized pharmaceutical business model, generating revenue from the production and sale of branded therapeutics in the United States, the United Kingdom, and various international markets. Its clientele includes healthcare providers, addiction treatment centers, and individuals impacted by opioid use disorder.
As of a recent Friday, Indivior's shares were trading at $36.02, marking an approximate 200% surge over the preceding year. This performance significantly outpaces the S&P 500, which recorded a gain of about 28% during the same timeframe. This strong stock appreciation suggests that Madison Avenue Partners perceives an ongoing undervaluation of Indivior's opioid treatment franchise within the market, despite its rapid ascent.
The primary catalyst behind Indivior's remarkable growth is SUBLOCADE, its long-acting medication for opioid use disorder. In the first quarter, SUBLOCADE's revenue surged by 32% year-over-year, reaching $232 million, which contributed to an overall 19% increase in total revenue to $317 million. Furthermore, the company's profitability saw an even more rapid expansion, with adjusted EBITDA more than doubling to a record $164 million, and GAAP net income climbing from $47 million to $89 million compared to the previous year.
The company's management has demonstrated strong confidence in its future trajectory. Indivior revised its full-year guidance upwards, projecting SUBLOCADE revenue to reach up to $990 million in 2026. Additionally, the company repurchased $125 million worth of stock during the quarter, with an additional $275 million remaining under its authorized buyback program. The critical question for investors moving forward is whether SUBLOCADE can sustain its market share growth within the expansive yet underserved opioid treatment landscape, acknowledging the inherent risk associated with a high concentration of investment in a single product for continued strong performance.
This major investment by Madison Avenue Partners into Indivior highlights a strategic bet on the sustained profitability and expansion of the pharmaceutical company, particularly driven by its innovative treatments for opioid use disorder. The impressive financial results and robust stock performance of Indivior over the past year indicate a strong market position and potential for continued growth, making it an attractive prospect for institutional investors seeking high-growth opportunities within the healthcare sector.
